




Six-month outcomes after treatment of a stenosed or occluded venous anastomosis of a synthetic arteriovenous (AV) access graft.¹


Findings from a prospective, real-world, multicenter study with the VIABAHN® Device from Japan.

VIABAHN® Device

Primary patency¹



Secondary patency¹



No statistical difference in target lesion primary patency with respect to¹:

- Crossing the elbow
- Sex
- Number of prior interventions
- Diabetes
- Age of circuit
- Stent graft size and location
- Stenosis vs. occlusion
- Elephant trunk placement (stent graft in the outflow vein lies without vessel wall apposition)

Patient characteristics N = 103

Female: 57.3%
Average age: 71.8 years
Average BMI (n = 76):
23.2 (kg/m²)
Diabetic nephropathy: 39.8%

Lesion characteristics N = 105

Average length (N = 93):
42.9 mm
Thrombosed: 22.9%

^a As used by Gore, PROPATEN Bioactive Surface refers to Gore's proprietary CBAS® Heparin Surface.

Expand your dialysis access options

Immediate

GORE® ACUSEAL Vascular Graft: Avoid or reduce CVC dependency with early cannulation within 24 hours²⁻⁴



Rapid

GORE® PROPATEN® Vascular Graft: Proven clinical performance when early cannulation is not required⁵



Durable

VIABAHN® Device: High patency and durable outcomes to minimize interventions for your patients^{6,7}



References

1. Haruguchi H, Fukasawa M, Ikeda K, *et al.* Treatment with a self-expanding endoprosthesis in patients with stenosis or occlusion at the arteriovenous graft: 6-month outcomes of a post-marketing surveillance study. *Journal of Vascular Access*. In press.
2. Glickman MH, Burgess J, Cull D, Roy-Chaudhury P, Schanzer H. Prospective multicenter study with a 1-year analysis of a new vascular graft used for early cannulation in patients undergoing hemodialysis. *Journal of Vascular Surgery* 2015;62(2):434-441.
3. Tozzi M, Franchin M, letto G, *et al.* Initial experience with the Gore® Acuseal graft for prosthetic vascular access. *Journal of Vascular Access* 2015;16(6):467-471.
4. Maytham GGD, Sran HK, Chemla ES. The use of the early cannulation prosthetic graft (Acuseal™) for angioaccess for haemodialysis. *Journal of Vascular Access* 2015;62(2):434-441.
5. Davidson I, Hackerman C, Kapadia A, Minhajuddin A. Heparin bonded hemodialysis e-PTFE grafts result in 20% clot free survival benefit. *Journal of Vascular Access* 2009;10(3):153-156.
6. Mohr BA, Sheen AL, Roy-Chaudhury P, Schultz SR, Aruny JE. REVISE Investigators. Clinical and economic benefits of stent grafts in dysfunctional and thrombosed hemodialysis access graft circuits in the REVISE Randomized Trial. *Journal of Vascular & Interventional Radiology* 2019;30(2):203-211.e4.
7. Vesely T, DaVanzo W, Behrend T, Dwyer A, Aruny J. Balloon angioplasty versus Viabahn stent graft for treatment of failing or thrombosed prosthetic hemodialysis grafts. *Journal of Vascular Surgery* 2013;64(5):1400-1410.e1. <http://www.sciencedirect.com/science/article/pii/S0741521416301756> Accessed August 23, 2021.

 Consult Instructions for Use
eifu.goremedical.com

Refer to *Instructions for Use* at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. Rx Only

Products listed may not be available in all markets.

© 2025 W. L. Gore & Associates, Inc. All rights reserved. All trademarks referenced are trademarks of either a member of the Gore group of affiliated companies or their respective owners. "Together, improving life" mark and design are trademarks of a Gore company. 25PL1088-EN01 AUGUST 2025

W. L. Gore & Associates, Inc.
goremedical.com

Asia Pacific +65 67332882 Australia / New Zealand 1800 680 424 Europe 00800 6334 4673
United States Flagstaff, AZ 86003 800 437 8181 928 779 2771

